Please select the option that best describes you:
With the increasing availability of biosimilars and their adoption onto payer formularies, how do you approach selection among available biosimilars in clinical practice?
Are there data or clinical experience that lead you to prefer certain biosimilars over others, particularly for adalimumab, rituximab, and infliximab?
Answer from: at Community Practice
Insurance payers consider FDA‑approved biosimilars to be clinically equivalent. In my experience, selection is ultimately driven by the insurance payer formulary - what you can get for the patient on the time. This can be fleeting and quickly changing at times. Cases can be made for patient experi...
Sign In or Register to read more